Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.

HIV/AIDS

Quick Links

Veterans Crisis Line Badge
My healthevet badge

Common Medications: ARV Interactions

for Health Care Providers

Common Medications: ARV Interactions

Back to Common Medications Chapter

MedicationARV InteractionsComments
Antiepileptic Medications: Carbamazepine, phenytoin, and phenobarbital may ↓ PI and NNRTI levels substantially.
Carbamazepine

CYP450 inducer
PIs: may ↓ PI levels
  • ATV: ↑ carbamazepine levels
  • DRV: ↑ carbamazepine levels; ↓ DRV levels
  • RTV: ↑ carbamazepine levels
  • TPV: ↑ carbamazepine levels; ↓ TPV levels
    Other PIs: may also ↑ carbamazepine levels
  • Avoid concomitant use if possible; use alternative antiepileptics.

  • Two-way interactions also affect PI and NNRTI levels.
NNRTIs: may ↓ levels of all NNRTIs
  • EFV: ↓ carbamazepine AUC 27%; ↓ EFV levels
  • ETR, RPV: expect ↓ NNRTIs levels
  • Avoid use with EFV, if possible; use alternative antiepileptics.
  • ETR and RPV should not be coadministered.
MVC:↓ MVC levelsIf used concurrently, give MVC 600 mg BID.
Phenobarbital

CYP450 inducer
PIs: may ↓ PI levels
  • DRV: ↓ phenobarbital levels
  • RTV: ↓ phenobarbital levels
  • TPV: ↓ phenobarbital levels and ↓ TPV levels
  • Avoid concomitant use if possible; use alternative antiepileptics.
  • Two-way interactions also affect PI and NNRTI levels.
NNRTIs: may ↓ NNRTI levels
  • EFV and NVP: ↓ phenobarbital levels
  • ETR: ↓ ETR levels
  • RPV: expect ↓ RPV levels
  • Avoid with EFV and NVP, if possible; use alternative antiepileptics.
  • ETR and RPV should not be coadministered.
MVC:↓ MVC levelsIf used concurrently, give MVC 600 mg BID.
Phenytoin

CYP450 inducer
PIs: may ↓ PI levels
  • DRV: ↓ phenytoin levels
  • FPV: ↓ phenytoin levels
  • LPV/r: ↓ LPV Cmin 46%, ↓ RTV Cmin 47%; ↓ phenytoin Cmin 34%
  • NFV: ↓ M8 levels 20-30%, ↓ phenytoin Cmin 39%
  • RTV: anticipate ↓ phenytoin levels
  • TPV: ↓ TPV levels
  • Avoid if possible; use alternative antiepileptics.


  • Two-way interactions also affect PI and NNRTI levels.
NNRTIs: may ↓ NNRTI levels
  • EFV: ↓ phenytoin levels, ↓ EFV levels
  • ETR: ↓ ETR levels
  • Avoid use with EFV if possible.

  • ETR and RPV should not be coadministered.
MVC:↓ MVC levelsIf used concurrently, give MVC 600 mg BID.
ValproatePIs
  • LPV/r: ↑ LPV Cmax 33%, ↑ AUC 75%, may ↓ valproate levels
  • RTV and TPV: ↓ valproate levels
Titrate to effect.
NNRTIs: no significant changes in NNRTI or valproate levels
Lamotrigine
  • LPV/r: ↓ lamotrigine levels 50%
  • RTV: ↓ lamotrigine levels
Titrate to effect.
Antifungal Medications
Fluconazole

Inhibitor of CYP 2C9
PIs
  • ATV/r: no significant change
  • TPV: ↑ TPV levels
TPV: Avoid fluconazole >200 mg daily.
NNRTIs
  • NVP: 100% ↑ in NVP levels
  • EFV: no significant change
  • ETR, RPV: potential ↑ in NNRTI levels
  • Avoid use with NVP.

  • EFV, ETR: dosage adjustment not required.
  • RPV: no data
Itraconazole

Inhibitor and substrate of CYP 3A4
PIs:↑ PI levels and ↑ itraconazole levels
  • LPV/r: ↑ itraconazole levels
Avoid itraconazole dosages >200 mg daily with patients who take PIs.
NNRTIs
  • EFV: ↓ itraconazole levels
  • ETR: ↓ itraconazole levels and ↑ ETR
  • NVP: ↓ itraconazole levels and ↑ NVP
  • RPV: not studied
  • If used concomitantly, consider monitoring itraconazole levels and adjust itraconazole dosage as necessary.
  • Avoid with ETR.
MVC:↑ MVC levelsMVC 150 mg BID
Ketoconazole:

Inhibitor and substrate of CYP 3A4
PIs: may ↑ PI levels and ↑ itraconazole levels
  • ATV/r, FPV/r: ↑ ketoconazole levels
  • DRV/r: ↑ ketoconazole levels, ↑ DRV levels
  • LPV/r: ↑ ketoconazole levels; may ↑ or ↓ LPV/r levels
Avoid ketoconazole dosages >200 mg daily with patients who take RTV-boosted PIs.
NNRTIs
  • EFV: no data
  • NVP, ETR, RPV: ↓ ketoconazole levels; ↑ NNRTI levels
  • Not recommended for use with NVP.
  • Dosage adjustment for interactions with ETR and RPV not established.
MVC:↑ MVC levelsMVC 150 mg BID
Posaconazole

Inhibitor of CYP 3A4
PIs
  • RTV: ↑ RTV levels
  • ATV: ↑ ATV levels
Monitor laboratory values frequently for signs of toxicity.
NNRTIs
  • EFV: ↓ posaconazole levels
  • ETR: ↑ ETR levels
  • RPV: not studied
  • Consider alternative antifungal or monitor posaconazole level.
  • Monitor for ETR-related adverse effects.
Terbinafine:

Inhibitor of CYP 2D6
PIs: no significant changesNo dosage adjustments necessary.
NNRTIs: no significant changesNo dosage adjustments necessary.
Voriconazole

CYP 3A4, CYP 2C9, and CYP 2C19 inhibitor; CYP 2C19 substrate
PIs: limited data
  • RTV: voriconazole AUC ↓ 39% with RTV 100 mg BID
Not recommended for use with RTV 100 mg QD or BID unless benefit outweighs risk. If used, consider monitoring voriconazole levels.
NNRTIs
  • EFV: substantial ↓ voriconazole and ↑ EFV; similar effect expected for NVP
  • ETR: ↑ voriconazole and ↑ ETR
  • RPV: not studied
  • EFV: contraindicated at standard dosages; use voriconazole 400 mg BID and EFV 300 mg QD.
  • ETR: dosage adjustments for ETR and voriconazole not established; use alternative antifungal or monitor voriconazole level and ETR adverse effects.
  • RPV: not studied
MVC: anticipated ↑ MVC levelsMVC 150 mg BID
Calcium Channel Blockers (CCBs)
Amlodipine
  • FPV, RTV, and SQV: ↑ amlodipine levels
  • IDV: ↑ amlodipine Cmax and AUC 89%
  • Incompletely studied.
  • PIs may inhibit metabolism of CCBs, increasing risk of adverse effects including hypotension, conduction block, and bradycardia.
  • NNRTIs may induce metabolism of CCBs, reducing their effect.
  • Avoid use in patients with CHF.
  • Avoid immediate-release forms.
Diltiazem
  • ATV: ↑ diltiazem Cmax 200%
  • IDV: ↑ diltiazem Cmax 25%
  • SQV/r: ↑ diltiazem levels
  • EFV: ↓ diltiazem AUC 70%
  • NVP: ↓ diltiazem levels
Methadone
PIs
  • ATV: ↓ total methadone AUC 6%; ↑ R-methadone AUC 3%, Cmin 11%
  • DRV/r: ↓ methadone AUC 16%
  • FPV: ↓ methadone AUC 18%
  • LPV/r: ↓ methadone AUC 53%
  • NFV: ↓ methadone AUC 47%
  • SQV/r: ↓ methadone AUC
  • TPV/r: ↓ methadone AUC 48%
  • Most PIs ↓ methadone levels, particularly LPV/r, NFV, and TPV.
  • Of NNRTIs, EFV and NVP ↓ methadone, whereas ETR is anticipated to have no effect. DLV ↑ methadone levels.
  • Monitor for methadone efficacy, and signs and symptoms of opiate withdrawal. Titrate dosage cautiously as needed.
NNRTIs
  • EFV: ↓ methadone AUC 60%
  • ETR: no change in methadone levels anticipated
  • NVP: ↓ methadone AUC 46%
  • RPV: ↓ methadone AUC 16%, ↓ Cmin 22%
  • Monitor for methadone efficacy and signs and symptoms of opiate withdrawal. Titrate methadone dosage cautiously as needed.
Warfarin
PIs
  • FPV, IDV, SQV, ATV: ↑ warfarin levels
  • LPV/r: may ↑ or ↓ warfarin levels
  • RTV: may ↓ warfarin levels
  • DRV: ↓ warfarin levels
  • TPV: no change in warfarin levels
  • Start at low dosage; monitor INR closely. Adjust warfarin dosage as indicated.
  • Monitor INR closely, may need increased warfarin dosage.
NNRTIs
  • EFV: warfarin levels may ↑ or ↓
  • NVP: ↓ warfarin levels (anticipated)
  • ETR: ↑ warfarin levels (anticipated)
  • RPV: not studied
Monitor INR closely, adjust dosage as indicated.

From Common Medications
Primary Care of Veterans with HIV
Office of Clinical Public Health Programs
Veterans Health Administration, 2009